Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw
© Vincenzi et al.; licensee BioMed Central Ltd. 2012
Received: 20 July 2012
Accepted: 25 July 2012
Published: 17 September 2012
Recent studies have been reported that angiogenesis suppression may play a role in developing bisphosphonate-related osteonecrosis of the jaw (B-ONJ). According to these evidence we evaluated the role of VEGF as predictive marker of B-ONJ onset. Of the 81 patients, 6 developed B-ONJ following bisphosphonate treatment. These patients showed a strongest decrease in VEGF circulating levels at day 7 and at day 21 after the first administration. These data demonstrated for the first time that the anti-angiogenic properties of bisphosphonates are directly linked to B-ONJ pathogenesis and serum VEGF levels could represent an effective early predictive marker.
KeywordsOsteonecrosis of the jaw Bisphosphonates Vascular endothelial growth factor (VEGF)
Letter to the editor
Bisphosphonate-related osteonecrosis of the jaw (B-ONJ) is defined as non-healing exposed bone in the mandible or maxilla persisting for more than 8 weeks in a patient with no history of radiation therapy on the jaws who has taken or is currently taking a bisphosphonate. B-ONJ is a well-known adverse effect reported in about 5% of patients with cancer receiving high-dose intravenous bisphosphonates .
B-ONJ pathogenesis is still uncertain and under debate; bisphosphonates indeed act on a wide variety of cells, possibly increasing susceptibility to infections in the oral cavity and impairing mucosal healing acting on monocyte differentiation, angiogenesis or both .
Recently, several cases of exposed bone in the mandible, with a very close clinical presentation to B-ONJ, have been reported in cancer patients treated with bevacizumab, a recombinant human monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis [2, 3]. According to popular hypothesis, angiogenesis suppression may indeed play a role in B-ONJ , even though evidences are currently lacking. Notably, vascular impairment is considered to be crucial in the pathogenesis of other bisphosphonate-unrelated osteonecrosis (e.g. osteoradionecrosis, avascular necrosis of the hip and corticosteroid-induced osteonecrosis).
Notably, beside known antiresorptive, immunomodulating and direct antitumor actions, bisphosphonates are now considered to be also anti-angiogenic drugs: in our three previous works we showed the reduction of circulating VEGF in cancer patients suffering from bone metastases after treatment with either zoledronic acid (standard schedule or metronomic administration) or pamidronate [5–7].
In order to evaluate the role of VEGF reduction as predictive marker of B-ONJ onset, we collected data from our three series involving a total of 81 patients. Of 81 patients, 6 (7.4%) developed B-ONJ following intravenous bisphosphonate administration (1 under treatment with pamidronate, 3 under treatment with zoledronic acid on standard schedule and 2 under treatment with zoledronic acid on metronomic administration). These 6 patients were affected by breast cancer (n = 3), prostate cancer (n = 2) and renal cancer (n = 1). The median number of bisphosphonates administrations was 9 in B-ONJ group vs. 11 in non-B-ONJ group (p = 0.196) and the median time of B-ONJ development was 9 months (range 6–22).
VEGF levels (pg/ml) at baseline, 7 and 21 days in patients who developed B-ONJ
VEGF levels (pg/ml)
To the best of our knowledge, this is the first evidence that the anti-angiogenic properties of bisphosphonates are directly linked to B-ONJ pathogenesis. If confirmed, serum VEGF levels at day 7 and 21 after the first administration of intravenous bisphosphonate could represent an effective early predictive marker of B-ONJ.Finally, we are aware that these data come from a very small retrospective analysis, but their potential impact in clinical practice warrants prospective studies and extensive validation by the entire medical community.
Bisphosphonate-related osteonecrosis of the jaw
Vascular endothelial growth factor.
- Reid IR, Cornish J: Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol. 2011, 8: 90-96.PubMedGoogle Scholar
- Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G, Huryn JM: Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008, 26: 4037-4038. 10.1200/JCO.2007.15.5424.View ArticlePubMedGoogle Scholar
- Greuter S, Schmid F, Ruhstaller T, Thuerlimann B: Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol. 2008, 19: 2091-2092. 10.1093/annonc/mdn653.PubMed CentralView ArticlePubMedGoogle Scholar
- Yin G, Bai Y, Luo E: Angiogenic suppression of osteoclasts may play a role in developing bisphosphonate-related osteonecrosis of the jaw. Med Hypotheses. 2011, 76: 347-349. 10.1016/j.mehy.2010.10.036.View ArticlePubMedGoogle Scholar
- Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G: Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003, 9: 2893-2897.PubMedGoogle Scholar
- Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G: Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002, 8: 1080-1084.PubMedGoogle Scholar
- Santini D, Vincenzi B, Tonini G, Scarpa S, Baldi A: Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003, 9: 3215-author reply 3216PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.